IND application accepted for phase I/Ib trial for CPI-818 for treating R/R T-cell lymphoma in China Aug. 17, 2021
TRIDENT-2 study evaluates repotrectinib combined with trametinib in KRAS G12D mutant solid tumors Aug. 17, 2021
RSS